乌司他丁联合胸腺肽α_1对急性颅脑损伤患者免疫功能的影响观察  

Influence of Ulinastatin Combined with Thymosin α_1 on Immune Function of Patients with Acute Brain Injury

作　　者：费毅[1] 王鹏程[1] 陈宝智[1] 陈建南[1] 彭其斌[1] 曾敏[1] Fei Yi Wang Pengcheng Chen Baozhi Chen Jiannan Peng Qibin Zeng Min(Department of Neurology, Peopleg Hospital in Hain- an, Haikou 570311, China)

机构地区：[1]海南省人民医院神经科,海口570311

出　　处：《中国药师》2017年第2期287-290,共4页China Pharmacist

基　　金：海南省自然科学基金项目(编号:20158349);海南省医学科研重点项目(编号:2012ZD-06)

摘　　要：目的:探讨乌司他丁联合胸腺肽α1对急性颅脑损伤患者免疫功能的影响。方法:急性颅脑损伤患者68例随机分为对照组与联合组各34例。对照组患者行常规治疗,联合组患者在对照组基础上加用乌司他丁联合胸腺肽α1治疗。分别于治疗后1,3,7,14 d检测两组患者转化生长因子-β1(TGF-β1)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)等血清炎症细胞因子水平,及CD4^+、CD8^+、CD4^+/CD8^+、人类白细胞DR抗原(HLA-DR)等细胞免疫指标水平;借助颅脑损伤预后恢复分级法评定两组患者预后效果,并对两组不良反应情况进行分析。结果:治疗后1 d两组患者血清炎症细胞因子及免疫指标水平比较差异均无统计学意义(P>0.05)。治疗后3,7,14 d两组患者血清TGF-β1、IL-6、IL-10、TNF-α水平均明显高于治疗后1 d水平(P<0.05);随时间延长,TGF-β1水平呈现升高趋势,IL-6、IL-10、TNF-α及CD4^+、CD4^+/CD8^+呈现先升高后降低的趋势,CD8^+、HLA-DR呈现先降低后升高的趋势;联合组治疗后3,7,14 d血清IL-10、CD4^+水平明显高于对照组,IL-6及TNF-α水平明显低于对照组(P<0.05),治疗后3,14 d时CD8^+水平明显高于对照组,治疗后7,14 d时HLA-DR水平明显高于对照组(P<0.05)。联合组患者预后情况好于对照组(P<0.05)。结论:急性颅脑损伤患者使用乌司他丁联合胸腺肽α1治疗,细胞免疫功能改善及预后效果均较好,值得临床推广应用。Objective： To explore the influence of ulinastatin combined with thymosin eq on the immune function of patients with a- cute brain injury. Methods： Sixty-eight cases of patients with acute brain injury were divided into the control group and the observation group randomly with thirty-four ones in each. The control group was given the routine treatment, and the observation group was given ulinastatin combined with thymosin cq additionally. After the 1-day, 3-day, 7-day and 14-day treatment, transforming growth factor-f31 （TGF-β1）, interleukin-6（IL-6）, interleukin-10 （IL-10）, tumor necrosis factor-or （TNF-α） and the other serum inflammatory cyto- kine levels, and CD4＋ , CD8 ＋ , CD4＋/CD8＋ , HLA-DR and cellular immune index levels were detected in the two groups. The prog- nosis effects were evaluated by the prognostic classification of brain injury, and the adverse reactions were analyzed in the two groups as well. Results： After the 1-day treatment, there were no significant differences in the serum inflammatory cytokines and immune param- eters between the groups （P 〉0.05）. After the 3-day, 7-day and 14-day treatment, serum TGF-β1, IL-6, IL-10 and TNF-α levels were higher than those on the first day after the treatment, and TGF-β1 showed an increasing trend with time extension, while IL-6, IL- 10, TNF-α and CD4＋ and CD4 ＋/CD8＋ rose first and then decreased. After the 3-day, 7-day and 14-day treatment, sertrm IL-10 and CD4＋ levels in the observation group were significantly higher than those in the control group, and IL-6 and TNF-α levels were signifi- cantly lower than those in the control group （ P 〈 0.05 ）. After the 3-day and 14-day treatment, CD4＋ and CD8＋ levels in the observa- tion were significantly higher than those in the control group, and after the 7-day and 14-day treatment, HLA-DR levels were signifi- cantly higher than those in the control group （P 〈 0.05 ）. The prognosis effect of the observation group was better than that of the con

关 键 词：乌司他丁 胸腺肽Α1 急性颅脑损伤 免疫功能 

分 类 号：R979.5[医药卫生—药品]